Solubility: Soluble in dimethyl sulfoxide at >20 mg/mL
pKa: 2.1 (at 25°C)
Storage Conditions
Store at 2-8°C.
Safety Information
Hazard Symbols: Xi
Risk Codes: 36/37/38
Safety Statements: 26-36
UN Number: UN 2811 6.1 / PGIII
WGK Germany: 3
Uses and Biological Activity
Dexrazoxane is a cardioprotectant and a lipophilic derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA). It readily penetrates cell membranes and is converted intracellularly into an open-ring chelator that interferes with the formation of iron-mediated free radicals, which is partially responsible for the cardiotoxicity of anthracycline antibiotics.
Dexrazoxane is currently the only clinically available agent for preventing anthracycline-induced cardiotoxicity. When combined with anthracyclines such as doxorubicin, it provides cardiac protection by reducing the formation of complexes between trivalent iron ions and anthracycline antineoplastic drugs, thereby preventing the generation of free radicals.
Dexrazoxane also inhibits the cytotoxic effects mediated by topoisomerase II.
In the treatment regimen for patients with advanced breast cancer, continuous infusion of dexrazoxane has been shown to provide cardiac protection when administered in combination with methotrexate, epirubicin, and folinic acid.
